References
- American Diabetes Association. Clinic practice recommendations 2004; Standard of medical care in diabetes. Diabetes Care 2004; 27(suppl 1):S15–S35.
- American Diabetes Association. Clinic practice recommendations 2004; Hypertension management in adults with diabetes. Diabetes Care 2004; 27(suppl 1):S65–S67.
- Kamoi K, Miyakoshi M, Soda S, Kaneko S, Nakagawa O. Usefulness of home blood pressure measurement in the morning in type 2 diabetic patients. Diabetes Care 2002; 25(12):2218–2223. [CSA]
- Kamoi K, Imamura Y, Miyakoshi M, Kobayashi C. Usefulness of home blood pressure measurement in the morning in type 1 diabetic patients. Diabetes Care 2003; 26(8):2473–2475. [CSA]
- Jermendy G, Ferenczi J, Hernandez E, Farkas K, Nadas J. Day-night blood pressure variation in normotensive and hypertensive NIDDM patients with asymptomatic autonomic neuropathy. Diabetes Res Clin Pract 1996; 34(2):107–114. [CSA], [CROSSREF]
- Takase B, Kitamura H, Noritake M, Nagase T, Kurita A, Ohsuzu F, Matsuoka T. Assessmentof diabetic autonomic neuropathy using twenty-four-hour spectral analysis of heart rate variability: a comparison with the findings of the Ewing battery. Jpn Heart J 2002; 43(2):127–135. [CSA], [CROSSREF]
- Pickering T G, Levenstein M, Walmsley P. Nighttime dosing of doxazosin has peak effect on morning ambulatory blood pressure results of the HALT study. Hypertension and lipid trial study group. Am J Hypertens 1994; 7(9 pt 1):844–847. [CSA]
- Hashimoto J, Chonan K, Aoki Y, Ugajin T, Yamaguchi J, Nishimura T, Kikuya M, Michimata M, Matsubara M, Araki T, Hozawa A, Ohkubo T, Imai Y. Therapeutic effects of evening administration of guanabenz and clonidine on morning hypertension: evaluation using home-based blood pressure measurements. J Hypertens 2003; 21(4):805–881. [CROSSREF]
- Rachmani R, Levi Z, Slavachevsky I, Half-Onn E, Ravid M. Effect of an alpha-adrenergic blocker, and ACE inhibitor and hydrochlorothiazide on blood pressure and on renal function in type 2 diabetic patients with hypertension and albuminuria. A randomized cross-over study. Nephron 1996; 80(2):75–82.
- The ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Collaborative Research Group. JAMA 2000; 283(15):1967–1975. [CROSSREF]
- Davis B R, Cutler J A, Furberg C D, Wright J T, Farber M A, Felicetta J V, Stokes J D, ALLHAT Collaborative Research Group. Relationship of antihypertensive treatment regimens and change in blood pressure to risk for heart failure in hypertensive patients randomly assigned to doxazosin or chlorthalidone: further analyses from the antihypertensive and lipid-lowering treatment to prevent heart attack trial. Ann Intern Med 2002; 137(5 Part 1):313–320.
- Barzilay J I, Davis B R, Bettencourt J, Margolis K L, Goff D C Jr, Black H, Habib G, Ellsworth A, Force R W, Wiegmann T, Ciocon J O, Basile J N, ALLHAT Collaborative Research Group. Cardiovascular outcomes using doxazosin vs. chlorthalidone for the treatment of hypertension in older adults with and without glucose disorders: a report from the ALLHAT study. J Clin Hypertens (Greenwich) 2004; 6(3):116–125. [CSA]
- Taylor S H. Clinical pharmacotherapeutics of doxazosin. Am J Med 1989; 87(suppl 2A):2S–11S. [CROSSREF]
- Ohkubo T, Asayama K, Kikuya M, Metoki H, Hoshi H, Hashimoto J, Totsune K, Satoh H, Imai Y, Ohasama Study. How many times should blood pressure be measured at home for better prediction of stroke risk? Ten-year follow-up results from the Ohasama study. J Hypertens 2004; 22(6):1099–1104. [CROSSREF]
- Tierney W M, Brunt M, Kesterson J, Zhou X H, L'Italien G, Lapuerta P. Quantifying risk of adverse clinical events with one set of vital signs among primary care patients with hypertension. Ann Fam Med 2004; 2(3):209–217. [CROSSREF]